Window Trial of Fluorescently Labeled Nivolumab (Nivo800) in High Grade Glioma (HGG)
Status:
NOT_YET_RECRUITING
Trial end date:
2031-01-01
Target enrollment:
Participant gender:
Summary
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulation of nivolumab-nivo800-which incorporates a near-infrared fluorescent dye to enable real-time visualization of drug distribution within tumor tissue.